Inactive Instrument

Highlights Neos Therapeutics, Inc.

Equities

NEOS

US64052L1061

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Aytu BioScience : Completes Merger With Neos Therapeutics	21-03-22	MT
Neos Therapeutics : Aytu BioScience Announces Close of Merger with Neos Therapeutics	21-03-21	PU
Aytu BioScience, Inc. completed the acquisition of Neos Therapeutics, Inc..	21-03-18	CI
Neos Therapeutics : Merger With Aytu BioScience Endorsed by Proxy Advisers Glass, Lewis	21-03-12	MT
Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience	21-03-12	GL
Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience	21-03-10	GL
Aytu BioScience : Neos Therapeutics Shareholders To Vote on Deal In March	21-02-10	MT
Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021	21-02-10	GL
Neos Therapeutics : Aytu BioScience and Neos Therapeutics Enter Definitive Merger Deal	20-12-10	MT
Aytu BioScience, Inc and Neos Therapeutics, Inc Merger Call	20-12-10	FA
Neos Therapeutics : Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue¹ Specialty Pharmaceutical Company	20-12-10	AQ
Aytu BioScience, Inc. entered into definitive merger agreement to acquire Neos Therapeutics, Inc. for $37.8 million.	20-12-09	CI
Neos Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-09	CI
Neos Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-10	CI
Neos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-11	CI
Neos Therapeutics, Inc. Expects to Initiate Phase 1 Ascending Dose Study of NT0502 in Second Half of 2020	20-03-30	CI
Neos Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2019	20-03-13	CI
Neos Therapeutics, Inc. Initiates and Completes Dosing in A Phase 1 Trial of Nt0502 for the Treatment of Chronic Sialorrhea	20-01-13	CI
Neos Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-08	CI
Neos Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Neos Therapeutics, Inc.

Equities

NEOS

US64052L1061

Highlights

Filters